U.S. FDA Extended Approval For Merck & Co., Inc.’s Steglujan (ertugliflozin and sitagliptin) Tablets For The Treatment Of Type 2 Diabetes

U.S. FDA approved Merck & Co., Inc.’s Steglujan Tablets for the treatment of Type 2 Diabetes

 

U.S. FDA (Food and Drug Administration) recently approved Merck & Co., Inc.’s Steglujan (ertugliflozin and sitagliptin) Tablets for the treatment of Type 2 Diabetes

Company: Merck & Co., Inc.

Brand Name:  Steglujan

Treatment for:  Diabetes Type 2

Dosage Form: Tablets

Generic name: ertugliflozin and sitagliptin

 

 

General information about Balcoltra

Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.

Steglujan is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate. Steglujan is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. 

Our App

Connect with us

Oddway on facebook Oddway on pinterest Oddway on VK Oddway on LinkedIn Oddway on Twitter

Contact Us

  • icon
    Address : 4216/20, Ground Floor, 1 Ansari Road, Daryaganj,
               New Delhi - 110002 (India)
  • icon
    Phone : +91-11-43526658
    Mobile : +91-9873336444
  • icon
    WhatsApp : +91-9873336444
    Viber          : +91-9873336444

Oddway International is a Pharmaceutical Exporter & Supplier of Generic Medicine and Online Pharmacy Distributor in India...Read More

Top